These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16481201)

  • 21. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
    González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
    Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
    Maliepaard M; van Gastelen MA; Tohgo A; Hausheer FH; van Waardenburg RC; de Jong LA; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2001 Apr; 7(4):935-41. PubMed ID: 11309344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
    Imai Y; Ishikawa E; Asada S; Sugimoto Y
    Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
    Generaux GT; Bonomo FM; Johnson M; Doan KM
    Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function.
    Tallkvist J; Yagdiran Y; Danielsson L; Oskarsson A
    Cell Biol Toxicol; 2015 Apr; 31(2):111-20. PubMed ID: 25791223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
    Salphati L; Plise EG; Li G
    Eur J Pharm Sci; 2009 Jun; 37(3-4):463-8. PubMed ID: 19491037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta.
    Grube M; Reuther S; Meyer Zu Schwabedissen H; Köck K; Draber K; Ritter CA; Fusch C; Jedlitschky G; Kroemer HK
    Drug Metab Dispos; 2007 Jan; 35(1):30-5. PubMed ID: 17020956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
    Huss WJ; Gray DR; Greenberg NM; Mohler JL; Smith GJ
    Cancer Res; 2005 Aug; 65(15):6640-50. PubMed ID: 16061644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
    Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
    Imai Y; Tsukahara S; Asada S; Sugimoto Y
    Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
    An G; Gallegos J; Morris ME
    Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture.
    Badolo L; Jensen B; Säll C; Norinder U; Kallunki P; Montanari D
    Xenobiotica; 2015 Feb; 45(2):177-87. PubMed ID: 25183402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein).
    Ji Y; Morris ME
    Mol Pharm; 2005; 2(5):414-9. PubMed ID: 16196494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
    van Loevezijn A; Allen JD; Schinkel AH; Koomen GJ
    Bioorg Med Chem Lett; 2001 Jan; 11(1):29-32. PubMed ID: 11140726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
    Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.